CalciMedica, Inc. (CALC)

OTCMKTS: CALC · Delayed Price · USD
0.00 (0.00%)
Jun 7, 2023, 12:00 AM EDT - Market open
Market Cap 4.32M
Revenue (ttm) n/a
Net Income (ttm) -44.74M
Shares Out 823.07K
EPS (ttm) -39.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,145
Open n/a
Previous Close 5.25
Day's Range n/a
52-Week Range 1.00 - 5.28
Beta n/a
Analysts Buy
Price Target 14.00 (+166.67%)
Earnings Date Jun 20, 2023

About CALC

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country United States
Stock Exchange OTCMKTS
Ticker Symbol CALC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for CALC stock is "Buy" and the 12-month stock price forecast is $14.0.

Price Target
(166.67% upside)
Analyst Consensus: Buy
Stock Forecasts


CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP

2 days ago - GlobeNewsWire

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimat...

2 weeks ago - GlobeNewsWire

CalciMedica Expands Executive Team with New Appointments

Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cun...

2 weeks ago - GlobeNewsWire

CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening infla...

3 weeks ago - GlobeNewsWire

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected...

2 months ago - GlobeNewsWire